NVNO Company Profile and Key Details

enVVeno Medical Corporation generated EPS of -$39.57 over the past year. Five-year average earnings growth is 36.26%. enVVeno Medical Corporation earnings surprise history is a mixed track record. The quarter that ended March 26, 2026, missed forecasts by 7.45%. The prior quarter beat by -23.33%. Over the last six quarters, Apple has recorded several small beats. These include 6.06% in October 30, 2024.

enVVeno Medical Corporation has 19.25 million shares outstanding. The public float is 17.80 million shares, elevated short interest at 2.60% of float. This equals 496.02 thousand shares. The short ratio is 3.05 days. Institutional investors hold 27.51% of the float. Insiders own 0.84%. Biodyne Holding, S.A. holds 1.41 million shares, BERMAN ROBERT ANDREW has 222.24 thousand shares and Jenusaitis Matthew has 16.54 thousand shares. Over the past six months, insider transactions show net selling. They sold 5.04 thousand shares across 2 transactions.

NVNO has shown mixed momentum, losing -0.94% over the past week and -55.11% over the past quarter, though year-to-date performance is up 3.76%. Short-term trend indicators are bullishly aligned (SMA20 2.38%, SMA50 -6.21%, SMA200 -83.78%). The stock’s 14-day RSI is 48.61 (neutral), while the ATR of 1.3 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -94.71% below its high and over 19.95% above its low. Average 10-day trading volume of 19.99 thousand shares is slightly above the 3-month average of 16.69 thousand, indicating heightened recent market interest.

enVVeno Medical Corporation (NASDAQ:NVNO) closed at $10.38 USD, losing -$0.30 (-2.81%) from the previous close of $10.68. The stock is currently mid-range between its 52-week high and low $8.67 and $196.70. With a market capitalization of about $171.30 thousand, enVVeno Medical Corporation is classified as a micro-cap and shows market-like volatility (beta ~1.08). Key stats such as the average daily volume over the past year has been around 16.33 thousand shares, volume is running light vs its 52-week average. Headquartered in Irvine, CA, enVVeno Medical Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Robert A. Berman, the company employs approximately 37 people and listed since May 31, 2018. enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease.

enVVeno Medical Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.02. This means the shares are trading above this model’s fair value.

enVVeno Medical Corporation trades at a P/E ratio of -0.32, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.23 suggesting the stock is closer to book value. The P/FCF stands at -0.01, also above market averages.

Our AI price prediction model suggests that enVVeno Medical Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.05%, with price expected at $10.80 by May 19, 2026, within a range of $9.89 to $11.67 3-Month Outlook: Projected rise of 11.85%, reaching $11.61 by July 31, 2026, with a range of $7.81 to $16.38. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by May 05, 2027, within a range of $0.00 to $7.04.

enVVeno Medical Corporation (NASDAQ:NVNO) shares are flat 3.76% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows enVVeno Medical Corporation trading at a premium to the broader market with a P/E of -0.32. Our AI forecast model points to short-term strength (4.05% over two weeks), a medium-term rise (11.85% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.